Vertex Pharmaceuticals Incorporated
Global biotechnology company
Based in MA
🤖
AI Overview
With $1.4M in lobbying spend across 29 quarterly filings, Vertex Pharmaceuticals Incorporated is a significant lobbying presence.
$1.4M
Total Lobbying Spend
29
Quarterly Filings
1
Lobbying Firms Used
9
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $200K |
| 2019 | $150K |
| 2020 | $150K |
| 2021 | $200K |
| 2022 | $200K |
| 2023 | $200K |
| 2024 | $150K |
| 2025 | $200K |
Lobbying Firms
STANTON PARK GROUP
What They Lobby For
- issues related to rare and orphan disease therapeutics; issues related to FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; promoting reimbursement policies that protect patient access to pharmaceuticals; reauthorization of the Prescription Drug User Fee Amendments (PDUFA); CHIP reauthorization orphan drug provisions of HR 1, Tax Cuts and Jobs Act
- issues related to rare and orphan disease therapeutics; issues related to FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; promoting reimbursement policies that protect patient access to pharmaceuticals; reauthorization of the Prescription Drug User Fee Amendments (PDUFA); CHIP reauthorization orphan drug tax credit, and orphan drug provisions of HR 1, Tax Cuts and Jobs Act Issues related to access to rare and orphan disease therapeutics under the enactment of ACA; Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing.
- Access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; pharmaceutical pricing; awareness of cystic fibrosis; promoting reimbursement policies that protect patient access to pharmaceuticals;
- Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis
- Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease
- Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease
- Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines;
- Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 7142 and S. 3832
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.